|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/03/16 Anika Therapeutics, Inc. 10-Q 3/31/16 65:2.6M Globenewswire Inc./FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 194K
2: EX-10.1 Material Contract HTML 115K
3: EX-10.2 Material Contract HTML 27K
4: EX-10.3 Material Contract HTML 26K
5: EX-10.4 Material Contract HTML 31K
6: EX-10.5 Material Contract HTML 25K
7: EX-31.1 Certification -- §302 - SOA'02 HTML 24K
8: EX-31.2 Certification -- §302 - SOA'02 HTML 24K
9: EX-32.1 Certification -- §906 - SOA'02 HTML 19K
16: R1 Document And Entity Information HTML 44K
17: R2 Condensed Consolidated Balance Sheets (Current HTML 98K
Period Unaudited)
18: R3 Condensed Consolidated Balance Sheets (Current HTML 39K
Period Unaudited) (Parentheticals)
19: R4 Condensed Consolidated Statements of Operations HTML 75K
and Comprehensive Income (Unaudited)
20: R5 Condensed Consolidated Statements of Cash Flows HTML 103K
(Unaudited)
21: R6 Note 1 - Nature of Business HTML 24K
22: R7 Note 2 - Basis of Presentation HTML 24K
23: R8 Note 3 - Recent Accounting Pronouncements HTML 32K
24: R9 Note 4 - Investments HTML 25K
25: R10 Note 5 - Fair Value Measurements HTML 51K
26: R11 Note 6 - Equity Incentive Plan HTML 30K
27: R12 Note 7 - Earnings Per Share ("Eps") HTML 32K
28: R13 Note 8 - Inventories HTML 26K
29: R14 Note 9 - Intangible Assets HTML 38K
30: R15 Note 10 - Goodwill HTML 25K
31: R16 Note 11 - Accrued Expenses HTML 27K
32: R17 Note 12 - Commitments and Contingencies HTML 26K
33: R18 Note 13 - Leases HTML 26K
34: R19 Note 14 - Income Taxes HTML 26K
35: R20 Note 15 - Segment and Geographic Information HTML 40K
36: R21 Note 5 - Fair Value Measurements (Tables) HTML 45K
37: R22 Note 6 - Equity Incentive Plan (Tables) HTML 24K
38: R23 Note 7 - Earnings Per Share ("Eps") (Tables) HTML 24K
39: R24 Note 8 - Inventories (Tables) HTML 26K
40: R25 Note 9 - Intangible Assets (Tables) HTML 32K
41: R26 Note 10 - Goodwill (Tables) HTML 25K
42: R27 Note 11 - Accrued Expenses (Tables) HTML 25K
43: R28 Note 15 - Segment and Geographic Information HTML 36K
(Tables)
44: R29 Note 1 - Nature of Business (Details Textual) HTML 19K
45: R30 Note 3 - Recent Accounting Pronouncements (Details HTML 23K
Textual)
46: R31 Note 4 - Investments (Details Textual) HTML 25K
47: R32 Note 5 - Fair Value of Financial Instruments HTML 32K
(Details)
48: R33 Note 6 - Equity Incentive Plan (Details Textual) HTML 37K
49: R34 Note 6 - Assumptions Used to Estimate Fair Value HTML 32K
of Stock Options and Stock Appreciation Rights
Awards (Details)
50: R35 Note 7 - Earnings Per Share ("Eps") (Details HTML 43K
Textual)
51: R36 Note 7 - Basic and Diluted Earnings Per Share HTML 27K
(Details)
52: R37 Note 8 - Inventories (Details) HTML 28K
53: R38 Note 9 - Intangible Assets (Details Textual) HTML 20K
54: R39 Note 9 - Intangible Assets (Details) HTML 44K
55: R40 Note 10 - Changes in the Carrying Value of HTML 23K
Goodwill (Details)
56: R41 Note 11 - Accrued Expenses (Details) HTML 35K
57: R42 Note 12 - Commitments and Contingencies (Details HTML 20K
Textual)
58: R43 Note 13 - Leases (Details Textual) HTML 36K
59: R44 Note 14 - Income Taxes (Details Textual) HTML 34K
60: R45 Note 15 - Segment and Geographic Information HTML 19K
(Details Textual)
61: R46 Note 15 - Product Revenue by Product Group HTML 26K
(Details)
62: R47 Note 16 - Product Revenue by Geographic Location HTML 27K
(Details)
64: XML IDEA XML File -- Filing Summary XML 104K
63: EXCEL IDEA Workbook of Financial Reports XLSX 47K
10: EX-101.INS XBRL Instance -- anik-20160331 XML 512K
12: EX-101.CAL XBRL Calculations -- anik-20160331_cal XML 101K
13: EX-101.DEF XBRL Definitions -- anik-20160331_def XML 701K
14: EX-101.LAB XBRL Labels -- anik-20160331_lab XML 561K
15: EX-101.PRE XBRL Presentations -- anik-20160331_pre XML 724K
11: EX-101.SCH XBRL Schema -- anik-20160331 XSD 118K
65: ZIP XBRL Zipped Folder -- 0001171843-16-009632-xbrl Zip 74K
Exhibit 10.4
AMENDMENT
TO THE LEASE AGREEMENT (Reg.ne 39 series 3T)
By and between
FIDIA FARMACEUTICI S.P.A. with legal domicile in Abano Terme (PD) via Ponte della Fabbrica 3/A, Italy, VAT Code 00204260285 (hereinafter “Fidia”)
and
ANIKA THERAPEUTICS S.r.l. with legal domicile in Abano Terme (PD) via Ponte della Fabbrica 3/B, Italy, VAT Code 03641500289 (hereinafter “Anika”)
(which shall hereinafter be jointly referred to as the “Parties,” and individually as a “Party”)
WHEREAS
on December 30, 2009, Fidia and Anika (formerly FAB S.r.l.) entered into a lease agreement (the “Agreement”), subsequently amended, in respect of leasing a certain Property (as defined in the Agreement).
Through this Amendment Fidia and Anika establish the following:
| 1) | The definitions contained in the Agreement shall have the same meanings in this Amendment to the Lease Agreement. |
| 2) | Effective January 1, 2012, Annex A to the Agreement is replaced by Annex A attached to this Amendment to the Lease Agreement. |
| 3) | Effective January 1, 2012, recital C) of the Agreement is amended as follows: |
| “The Lessor is the owner of the leased premises in Abano Terme (PD), via Ponte della Fabbrica 3/A and 3/B, registered in the NCT.F. 10 map 632 and NCEU F. 10 map 632, as described in the registry search and plans as attached in Annex A hereto and identified as follows (the “Property”) |
| (1) | a portion of the building called F2 (“Building F2 – plans 0008_59 and 0008_02”), with 423 m2 to be used as a warehouse; |
| (2) | a portion of the building called “Research Institute” (LR1 – plans 0005 and 0006), with 1,174 m2 to be used as laboratories and Tissue Tech production facilities, and 1,268 m2 for office use (ground floor and first floor); |
C:
| - C: 1- |
| 4) | Effective from January 1, 2012 to March 31, 2012: |
| a) | the table contained in Section 3.1 is replaced by the following table which takes into account the ISTAT indexation at December 2011: |
| Area | M2 |
Monthly rent / m2 (euros) |
Monthly rent (euros) |
|
Research Institute (LR1 – plans 0005 and 0006) – Offices Warehouse (“Building F2 – plans 0008_59”) |
1,268 | 14.63 | 18,551 |
| 373 | 5.23 | 1,951 | |
|
Warehouse (“Building F2 – plans 0008_02”) |
50 | 14.63 | 732 |
|
Research Institute (LR1 – plan 0005) – Research Laboratories |
655 | 17.46 | 11,436 |
|
Research Institute (LR1 – plan 0006) – Tissue Tech Production Facilities |
519 | 17.46 | 9,062 |
| Totals | 2,865 | 41,732 |
and b) the total amount of the monthly rent in line with the provisions of Section 3.1, effective from January 1, 2012 to 03.31.2012, is 41,732 euros.
C:
| -2- |
| 5) | Effective April 1, 2012, the premises leased to Anika are reduced and therefore the spaces being leased are the ones indicated in Annex B of this Amendment to the Lease Agreement. |
| 6) | Effective from April 1, 2012, recital C) of the Agreement is amended as follows: |
| “The Lessor is the owner of the leased premises in Abano Terme (PD), via Ponte della Fabbrica 3/A and 3/B, registered in the NCT.F. 10 map 632 and NCEU F. 10 map 632, as described in the registry search and plans as attached in Annex A hereto and identified as follows (the “Property”) |
| (3) | a portion of the building called F2 (“Building F2 – plans 0008_59 and 0008_02”), with 423 m2 to be used as a warehouse; |
| (4) | a portion of the building called “Research Institute” (LR1 – plans 0005 and 0006), with 1,054 m2 to be used as laboratories and Tissue Tech production facilities, and 1,125 m2 for office use (ground floor and first floor); |
| 7) | Effective from April 1, 2012, the table contained in Section 3.1 is replaced by the following table: |
| Area | M2 |
Monthly rent / m2 (euros) |
Monthly rent (euros) |
|
Research Institute (LR1 – plans 0005 and 0006) – Offices Warehouse (“Building F2 – plans 0008_59”) |
1,125 | 14.63 | 16,459 |
| 373 | 5.23 | 1,951 | |
|
Warehouse (“Building F2 – plans 0008_02”) |
50 | 14.63 | 732 |
|
Research Institute (LR1 – plan |
535 | 17.46 | 9,341 |
C:
| -3- |
| 0005) – Research Laboratories | |||
|
Research Institute (LR1 – plan 0006) – Tissue Tech Production Facilities |
519 | 17.46 | 9,062 |
| Totals | 2,602 | 37,545 |
| Therefore, the total amount of the monthly rent in line with the provisions of Section 3.1 effective from April 1, 2012, is 37,545 euros. |
| 8) | With the return of the R&D spaces, Anika shall reimburse Fidia the sum of €24,666.00 pursuant to Art. 4 of the Lease Agreement of June 18, 2010. |
| 9) | The other provisions of the agreement remain unchanged. |
C:
| -4- |
IN WITNESS WHEREOF, the Parties have signed this Amendment to the Lease Agreement on
Abano Terme, April 16, 2012
FIDIA FARMACEUTICI S.P.A.
By: /s/ Antonio Germani
Antonio Germani, Managing Director
ANIKA THERAPEUTICS S.r.l.
By: /s/ Charles H. Sherwood, Ph.D.
Charles Sherwood, President
-5-
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 5/3/16 | |||
| For Period end: | 3/31/16 | |||
| 4/16/12 | ||||
| 4/1/12 | ||||
| 3/31/12 | 10-Q | |||
| 1/1/12 | ||||
| 6/18/10 | ||||
| 12/30/09 | 3, 8-K, 8-K/A | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/26/21 Anika Therapeutics, Inc. 10-K/A 12/31/20 100:10M Globenewswire Inc./FA 3/05/21 Anika Therapeutics, Inc. 10-K 12/31/20 105:11M Globenewswire Inc./FA |